BTIG reiterates Buy on MiniMed Group stock, $25 target on AID growth

BTIG reiterated a Buy and $25 price target on MiniMed Group (MMED), whose shares trade at $14.35 (near a 52-week low of $14.10) after a 12% decline over the past week. MiniMed reports $2.9bn LTM revenue and a 57% gross margin; BTIG projects ~10% revenue CAGR and EBITDA margin expansion from mid-teens into the 20s and values the firm at ~10x EV/adj EBITDA and ~2x EV/Sales on 12–24 month forecasts. FDA cleared the MiniMed Flex tubed pump months early, enabling an accelerated U.S. launch; Blackstone Life Sciences Advisors will receive royalties or a minimum $157m over the first two years post-launch. Additional analyst coverage includes Mizuho Outperform $21 PT, Morgan Stanley Overweight $19 PT, and Piper Sandler Neutral $16 PT.

Analysis

Full-stack positioning is the key structural winner: a vendor that controls sensor, pump, algorithm and front-end software creates optionality to capture both device and recurring software/servicing economics, and that vertical control short-circuits margin leakage to third-party integrators. Expect adjacent beneficiaries in the short run to be mobile-health/cloud vendors and contract manufacturers that scale patch-pump production; conversely, pure-play CGM suppliers and pump-only vendors face margin compression if pricing competition or bundled reimbursement accelerates.

Primary downside paths are commercial/reimbursement and execution cadence rather than pure technology risk — a slower-than-expected pharmacy transition, payer pushback on bundle pricing, or supply constraints for the new pump line can shave multiples quickly because the market is pricing margin expansion into near-term forecasts. Key catalysts over the next 3–24 months are initial U.S. commercial sell-through datapoints, first international rollouts, and pivotal-algorithm readouts; misses on any of these will amplify downside given leverage in EBITDA expansion assumptions.

Consensus optimism underweights two second-order drags: (1) near-term cashflow dilution from structured royalty/minimum payments to life-science investors, which compresses early free-cash-flow conversion even as revenue ramps, and (2) incremental SG&A as a standalone public company competing for pharmacy shelf/rehab dollars. That combination makes the 12–24 month path binary — execution wins can re-rate toward premium multiples, but small misses produce materially lower outcomes, creating asymmetric payoff for event-driven entry points and hedged exposure.

Key Decisions for Investors

• Core long MMED equity (12–24 month horizon): establish a modest starter position (1–2% NAV) to capture execution upside; scale on first U.S. commercial beat and international expansion evidence. Use a hard stop at -30% and target 2x–3x upside if revenue growth sustains and EBITDA margins expand toward consensus.
• Options trade — capped upside spread (6–18 months): buy a 12–18 month call spread with long strike ~30–50% above current levels and short strike ~60–90% above current to limit premium outlay (position size 0.3–0.6% NAV). Rationale: asymmetric payoff if launches accelerate; downside limited to premium.
• Event-driven pair (6–12 months): long MMED / short DXCM (or short combination of CGM-first vendors) notional ratio ~1:0.4 to hedge CGM-commodity risk. This isolates execution on closed-loop adoption; if MMED wins funnel share, pair should outperform while limiting exposure to CGM pricing pressure.
• Acquirer optionality hedge (12–18 months): overweight MDT on drawdown as a tactical play (0.5–1% NAV). If standalone execution disappoints, strategic re-consolidation interest from larger medtechs could reprice assets; risk: MDT exposure if broader medtech multiples compress.